A study to test the hypothesis that insulin resistance results in increased lipid peroxides/oxidative stress, which predisposes pregnant women to the development of preeclampsia. Preeclampsia, or toxemia of pregnancy, is a major cause of medical problems in pregnant women and newborns. It can cause high blood pressure, in the mother, which can lead to kidney and liver problems, seizures, and even death. It can cause low birth weight and delivery problems. The cause is not fully understood and a method of prevention has not been discovered. The patients in this study will have been screened and found to have higher than normal insulin levels. This is an indication that the patient may be at increased risk of developing preeclampsia. Participation in this study will help investigators devise a screening test for women at risk and will help them better understand the cause of preeclampsia, therefore prevention and even a cure may be discovered. Normal prenatal care will occur. At 28 weeks of pregnancy, during the normal test for diabetes (Glucola Challenge Test), additional blood will be drawn (approx. two tablespoons). Additional blood samples will be drawn at 31 and 34 weeks, at the time of delivery, and at the post-partum check up. These blood tests will measure various substances in the blood that may be involved in the development of preeclampsia. After delivery, a sample of the placenta will be evaluated to determine if it produces substances that contribute to preeclampsia problems.

Project Start
1999-12-01
Project End
2000-11-30
Budget Start
1998-10-01
Budget End
1999-09-30
Support Year
38
Fiscal Year
2000
Total Cost
$648
Indirect Cost
Name
Virginia Commonwealth University
Department
Type
DUNS #
City
Richmond
State
VA
Country
United States
Zip Code
23298
Holkova, Beata; Yazbeck, Victor; Kmieciak, Maciej et al. (2017) A phase 1 study of bortezomib and romidepsin in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma, indolent B-cell lymphoma, peripheral T-cell lymphoma, or cutaneous T-cell lymphoma. Leuk Lymphoma 58:1349-1357
Corey, Kathleen E; Vuppalanchi, Raj; Vos, Miriam et al. (2015) Improvement in liver histology is associated with reduction in dyslipidemia in children with nonalcoholic fatty liver disease. J Pediatr Gastroenterol Nutr 60:360-7
Eaton, J E; Juran, B D; Atkinson, E J et al. (2015) A comprehensive assessment of environmental exposures among 1000 North American patients with primary sclerosing cholangitis, with and without inflammatory bowel disease. Aliment Pharmacol Ther 41:980-90
Worthington Jr, Everett L; Berry, Jack W; Hook, Joshua N et al. (2015) Forgiveness-reconciliation and communication-conflict-resolution interventions versus retested controls in early married couples. J Couns Psychol 62:14-27
Holkova, Beata; Kmieciak, Maciej; Perkins, E Brent et al. (2014) Phase I trial of bortezomib (PS-341; NSC 681239) and ""nonhybrid"" (bolus) infusion schedule of alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory indolent B-cell neoplasms. Clin Cancer Res 20:5652-62
Poklepovic, Andrew; Youssefian, Leena E; Youseffian, Leena et al. (2013) Phase I trial of bortezomib and dacarbazine in melanoma and soft tissue sarcoma. Invest New Drugs 31:937-42
Holkova, Beata; Supko, Jeffrey G; Ames, Matthew M et al. (2013) A phase I trial of vorinostat and alvocidib in patients with relapsed, refractory, or poor prognosis acute leukemia, or refractory anemia with excess blasts-2. Clin Cancer Res 19:1873-83
Lo, D J; Farris, A B; Song, M et al. (2013) Inhibition of ?v?6 promotes acute renal allograft rejection in nonhuman primates. Am J Transplant 13:3085-93
Jones, Robert; Vuky, Jacqueline; Elliott, Tony et al. (2013) Phase II study to assess the efficacy, safety and tolerability of the mitotic spindle kinesin inhibitor AZD4877 in patients with recurrent advanced urothelial cancer. Invest New Drugs 31:1001-7
Al Hawaj, M A; Martin, E J; Venitz, J et al. (2013) Monitoring rFVIII prophylaxis dosing using global haemostasis assays. Haemophilia 19:409-14

Showing the most recent 10 out of 367 publications